Hey at least they are consistent

“Sanofi (EURONEXT: SAN and NYSE: SNY) and Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) announced today that they have entered into a collaboration and license agreement for the development and commercialization of sotagliflozin, an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT-1 and SGLT-2), which could be a potential treatment option for people with diabetes.” – Lexicon press release November 5, 2015

“In an 8-8 vote on Thursday, an FDA advisory panel was divided on whether to recommend approval of Sanofi and Lexicon Pharmaceutical's investigational diabetes drug Zynquista (sotagliflozin). “ FirstWord Pharma January 18, 2019 . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.